Brokerages Expect RedHill Biopharma Ltd (RDHL) to Announce -$0.57 Earnings Per Share

Wall Street analysts expect that RedHill Biopharma Ltd (NASDAQ:RDHL) will announce earnings of ($0.57) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for RedHill Biopharma’s earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.54). RedHill Biopharma posted earnings per share of ($0.50) during the same quarter last year, which would indicate a negative year over year growth rate of 14%. The business is scheduled to report its next earnings results on Wednesday, May 2nd.

According to Zacks, analysts expect that RedHill Biopharma will report full-year earnings of ($1.95) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.90). For the next financial year, analysts expect that the firm will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.30) to ($1.20). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for RedHill Biopharma.

How to Become a New Pot Stock Millionaire

RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.15. The firm had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.89 million.

Several equities research analysts recently weighed in on the company. Nomura assumed coverage on RedHill Biopharma in a research report on Friday, January 26th. They set a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research lowered RedHill Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, November 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. RedHill Biopharma presently has an average rating of “Buy” and an average target price of $19.70.

RDHL stock traded down $0.12 during midday trading on Friday, hitting $5.43. The company had a trading volume of 30,629 shares, compared to its average volume of 52,045. RedHill Biopharma has a one year low of $4.30 and a one year high of $11.25. The company has a market capitalization of $118.07, a price-to-earnings ratio of -2.17 and a beta of 0.53.

A number of large investors have recently made changes to their positions in the business. 683 Capital Management LLC purchased a new position in RedHill Biopharma during the fourth quarter valued at $5,136,000. Creative Planning purchased a new position in RedHill Biopharma during the fourth quarter valued at $722,000. Virtu Financial LLC purchased a new position in RedHill Biopharma during the fourth quarter valued at $312,000. Meitav Dash Investments Ltd. purchased a new position in RedHill Biopharma during the fourth quarter valued at $244,000. Finally, Family Management Corp raised its stake in RedHill Biopharma by 46.6% during the third quarter. Family Management Corp now owns 37,750 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 12,000 shares during the last quarter. Institutional investors and hedge funds own 15.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3296226/brokerages-expect-redhill-biopharma-ltd-rdhl-to-announce-0-57-earnings-per-share.html.

RedHill Biopharma Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions.

Get a free copy of the Zacks research report on RedHill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Virtus Investment Partners  Scheduled to Post Quarterly Earnings on Thursday
Virtus Investment Partners Scheduled to Post Quarterly Earnings on Thursday
NXP Semiconductors  Scheduled to Post Quarterly Earnings on Wednesday
NXP Semiconductors Scheduled to Post Quarterly Earnings on Wednesday
CEVA  to Release Earnings on Wednesday
CEVA to Release Earnings on Wednesday
Ottawa Savings Bancorp  Scheduled to Post Earnings on Thursday
Ottawa Savings Bancorp Scheduled to Post Earnings on Thursday
FIG Partners Comments on First Connecticut Bancorp’s FY2018 Earnings
FIG Partners Comments on First Connecticut Bancorp’s FY2018 Earnings
Brokers Offer Predictions for Ramaco Resources’ FY2018 Earnings
Brokers Offer Predictions for Ramaco Resources’ FY2018 Earnings


© 2006-2018 Ticker Report. Google+.